I have a hard time believing the trial wouldnt have hit the OS endpoint if given a little more maturity.
This abi trial had a higher (practical) hurdle than the usual. In practice (not per protocol), not only the trial had to show good OS benefit by reaching statistical significance, the OS benefit had to be better than abi's post-chemo benefit.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.